ব্ৰেষ্ট কেন্সাৰ
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
ক’ত যাব
ভাৰতৰ 1 খন হস্পিতালত এই trial-ৰ বাবে ৰোগী ভৰ্তি কৰা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety profile by eliminating excipients, polysorbate 80 and ethanol which are present in conventional Docetaxel formulations (Taxotere®). This randomized, open-label study is designed to assess the efficacy and safety of Nanosomal Docetaxel Lipid Suspension at the dose of 75 mg/m2 and at the dose of 100 mg/m2 compared to Taxotere® at the dose of 100 mg/m2 in triple-…
স্পনছৰ: Jina Pharmaceuticals Inc.
ClinicalTrials.gov-ত NCT03671044
ৰেজিষ্ট্ৰীত শেষ আপডেট 21 Mar 2025 · আমি পঢ়িছোঁ 20 Oct 2026